Friendly A positive Widal result does not reliably confirm typhoid because antibodies can reflect previous exposure or ...
FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.
Hibsago, the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B, reduces the amount of virus and hepatitis B surface antigen in the body.
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential. Bepirovirsen is specifically approved for patients ...
The FDA approved bepirovirsen as the first antisense oligonucleotide for chronic hepatitis B virus infection, alongside existing antiviral therapy for eligible adults without cirrhosis. Bepirovirsen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results